Palantir is a strong buy with booming AI platforms, 29% revenue growth, and strategic positioning in the AI arms race. Click ...

Tesla's Q1 delivery drop suggests disappointing earnings. Trade impacts and Musk's politics add pressure. Check out our ...

Metro has been outperforming the market during these volatile times, and its Q2 results were relatively strong. Find out why ...

At a market cap of 4.7B EUR and EV/EBITDA of 4.8, Arkema is attractively priced, even with a potential 15% EBITDA reduction.

When markets move, we can learn a lot from the outperformers. But we can also learn a lot from the underperformers - and ...

KREF's Series A is attractively priced for a company with a credit rating of B+. Though current yields of near 9% exist, ...

Adriatic Metals PLC upgraded to Buy due to Vareš project ramp-up, expected commercial production in Q1 2025, and favorable ...

Rocket Lab's heavy reliance on government contracts makes it especially vulnerable to cost-cutting in this sector. Check out ...

VitalHub, a healthcare software provider, has seen an 18% drop since January 2025 despite a 30% revenue growth during FY2024.

Geopolitical tensions are impacting markets, from luxury to gold. Read here for strategies to hedge wisely, spot ...

OPTZ, a unique all-cap ETF with GARP features. Low 14.77x P/E and high-growth potential, but higher risk. See more on OPTZ ...

By Diederik StadigUS President Donald Trump signed a new executive order on 15 April aimed at bringing US drug prices down.